Sunil Bhandari

List of Publications by Year
in descending order

160 papers	12,582 citations	101543 36 h-index	31849 101 g-index
165 all docs	165 docs citations	165 times ranked	17500 citing authors

#	Article	IF	Citations
1	Should We STOP Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Advanced Kidney Disease?. Nephron, 2016, 133, 147-158.	1.8	8,212
2	Intravenous Iron in Patients Undergoing Maintenance Hemodialysis. New England Journal of Medicine, 2019, 380, 447-458.	27.0	321
3	Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2020, 97, 42-61.	5.2	260
4	Incidence of renal dysfunction over 6 months in patients with chronic heart failure due to left ventricular systolic dysfunction: contributing factors and relationship to prognosis. European Heart Journal, 2006, 27, 569-581.	2.2	203
5	Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease. BMC Nephrology, 2017, 18, 345.	1.8	179
6	Determinants and Consequences of Renal Function Variations With Aldosterone Blocker Therapy in Heart Failure Patients After Myocardial Infarction. Circulation, 2012, 125, 271-279.	1.6	136
7	Anemia, Renal Dysfunction, and Their Interaction in Patients With Chronic Heart Failure. American Journal of Cardiology, 2006, 98, 391-398.	1.6	125
8	Enhancing the interlayer tensile strength of 3D printed short carbon fiber reinforced PETG and PLA composites via annealing. Additive Manufacturing, 2019, 30, 100922.	3.0	117
9	A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia. Journal of the American Society of Nephrology: JASN, 2019, 30, 1723-1733.	6.1	100
10	The Effect of Iron and Erythropoietin Treatment on the A1C of Patients With Diabetes and Chronic Kidney Disease. Diabetes Care, 2010, 33, 2310-2313.	8.6	93
11	Current misconceptions in diagnosis and management of iron deficiency. Blood Transfusion, 2017, 15, 422-437.	0.4	83
12	Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial. Nephrology Dialysis Transplantation, 2016, 31, gfv346.	0.7	81
13	State of the iron: How to diagnose and efficiently treat iron deficiency anemia in inflammatory bowel disease. Journal of Crohn's and Colitis, 2013, 7, 429-440.	1.3	71
14	A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia. Nephrology Dialysis Transplantation, 2016, 31, 646-655.	0.7	70
15	Expression of Somatostatin and Somatostatin Receptor Subtypes 1â€“5 in Human Normal and Diseased Kidney. Journal of Histochemistry and Cytochemistry, 2008, 56, 733-743.	2.5	61
16	Safety and efficacy ofÂiron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial. Nephrology Dialysis Transplantation, 2021, 36, 111-120.	0.7	61
17	The prevalence of potentially inappropriate medication prescribing in elderly patients with chronic kidney disease. Postgraduate Medical Journal, 2013, 89, 247-250.	1.8	60
18	A randomized, open-label trial of iron isomaltoside 1000 (MonoferÂ®) compared with iron sucrose (VenoferÂ®) as maintenance therapy in haemodialysis patients. Nephrology Dialysis Transplantation, 2015, 30, 1577-1589.	0.7	60

#	Article	IF	Citations
19	Epidemiology, Associated Factors, and Prognostic Outcomes of Renal Artery Stenosis in Chronic Heart Failure Assessed by Magnetic Resonance Angiography. American Journal of Cardiology, 2007, 100, 273-279.	1.6	58
20	Uremic Cardiomyopathy and Insulin Resistance. Journal of the American Society of Nephrology: JASN, 2011, 22, 207-215.	6.1	57
21	Intravenous Irons: From Basic Science to Clinical Practice. Pharmaceuticals, 2018, 11, 82.	3.8	55
22	Intravenous Iron Dosing and Infection Risk in Patients on Hemodialysis: A Prespecified Secondary Analysis of the PIVOTAL Trial. Journal of the American Society of Nephrology: JASN, 2020, 31, 1118-1127.	6.1	55
23	Atherosclerotic renovascular disease in chronic heart failure: should we intervene?. European Heart Journal, 2005, 26, 1596-1605.	2.2	48
24	Mortality at Low and High Estimated Glomerular Filtration Rate Values: A â€˜Uâ€™ Shaped Curve. Nephron Clinical Practice, 2008, 110, c67-c72.	2.3	47
25	Tolerability and efficacy of parenteral iron therapy in hemodialysis patients, a comparison of preparations. Transfusion Alternatives in Transfusion Medicine, 2007, 9, 37-42.	0.2	46
26	High glucose enhances store-operated calcium entry by upregulating ORAI/STIM via calcineurin-NFAT signalling. Journal of Molecular Medicine, 2015, 93, 511-521.	3.9	45
27	The safety of available treatment options for iron-deficiency anemia. Expert Opinion on Drug Safety, 2018, 17, 149-159.	2.4	45
28	Evaluation of RBC ferritin and reticulocyte measurements in monitoring response to intravenous iron therapy. American Journal of Kidney Diseases, 1997, 30, 814-821.	1.9	44
29	Safety of intravenous iron use in chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2016, 25, 529-535.	2.0	44
30	Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease. Journal of Nephrology, 2011, 24, 589-596.	2.0	44
31	Efficacy and safety of iron isomaltoside (Monofer®) in the management of patients with iron deficiency anemia. International Journal of Nephrology and Renovascular Disease, 2016, 9, 53.	1.8	43
32	Renal aspects of thalassaemia a changing paradigm. European Journal of Haematology, 2012, 89, 187-197.	2.2	42
33	Update of a comparative analysis of cost minimization following the introduction of newly available intravenous iron therapies in hospital practice. Therapeutics and Clinical Risk Management, 2011, 7, 501.	2.0	40
34	ORAI channels are critical for receptor-mediated endocytosis of albumin. Nature Communications, 2017, 8, 1920.	12.8	39
35	Oxidative Stress and Cardiovascular Complications in Chronic Kidney Disease, the Impact of Anaemia. Pharmaceuticals, 2018, 11, 103.	3.8	39
36	Side effects of Deferasirox Iron Chelation in Patients with Beta Thalassemia Major or Intermedia. Oman Medical Journal, 2013, 28, 121-124.	1.0	38

#	Article	IF	Citations
37	Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial. Nephrology Dialysis Transplantation, 2017, 32, 1530-1539.	0.7	38
38	A systematic review of known interventions for the treatment of chronic nonhypovolaemic hypotonic hyponatraemia and a metaâ€analysis of the vaptans. Clinical Endocrinology, 2017, 86, 761-771.	2.4	36
39	Finite element analysis of thermoplastic polymer extrusion 3D printed material for mechanical property prediction. Additive Manufacturing, 2018, 22, 187-196.	3.0	35
40	Effect of conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium on maximum tolerated dose and gastrointestinal symptoms following kidney transplantation. Transplant International, 2009, 22, 821-830.	1.6	34
41	Mitochondrial dysfunction in uremic cardiomyopathy. American Journal of Physiology - Renal Physiology, 2015, 308, F579-F587.	2.7	34
42	Measurement of Glutathione as a Tool for Oxidative Stress Studies by High Performance Liquid Chromatography. Molecules, 2020, 25, 4196.	3.8	32
43	ACE inhibitors and ARBs: Managing potassium and renal function. Cleveland Clinic Journal of Medicine, 2019, 86, 601-607.	1.3	32
44	Randomized Trial Comparing Proactive, High-Dose versus Reactive, Low-Dose Intravenous Iron Supplementation in Hemodialysis (PIVOTAL): Study Design and Baseline Data. American Journal of Nephrology, 2018, 48, 260-268.	3.1	30
45	Cathasept Line Lock and Microbial Colonization of Tunneled Hemodialysis Catheters: A Multicenter Randomized Controlled Trial. American Journal of Kidney Diseases, 2015, 66, 1015-1023.	1.9	28
46	Myocardial Function, Energy Provision, and Carnitine Deficiency in Experimental Uremia. Journal of the American Society of Nephrology: JASN, 2007, 18, 84-92.	6.1	26
47	Effects of applying a standardised management algorithm for moderate to severe renal dysfunction in patients with chronic stable heart failure. European Journal of Heart Failure, 2007, 9, 415-423.	7.1	22
48	Improving efficiency and value in health careâ€Intravenous iron management for anaemia associated with chronic kidney disease: linking treatment to an outpatient clinic, optimizing service provision and patient choice. Journal of Evaluation in Clinical Practice, 2008, 14, 996-1001.	1.8	22
49	Hypochloraemia in Patients with Heart Failure: Causes and Consequences. Cardiology and Therapy, 2020, 9, 333-347.	2.6	22
50	Randomized Trialâ€”PrEscription of intraDialytic exercise to improve quAlity of Life in Patients Receiving Hemodialysis. Kidney International Reports, 2021, 6, 2159-2170.	0.8	22
51	Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol. Transplantation Research, 2013, 2, 7.	1.5	21
52	Risk factors and metabolic mechanisms in the pathogenesis of uraemic cardiac disease. Frontiers in Bioscience - Landmark, 2011, 16, 1364.	3.0	20
53	Lesson of the week: Man's best friend: life threatening sepsis after minor dog bite. BMJ: British Medical Journal, 1997, 314, 129-129.	2.3	20
54	Photopheresis therapy for problematic renal allograft rejection. Journal of Clinical Apheresis, 2009, 24, 161-169.	1.3	19

#	Article	IF	Citations
55	Hypophosphataemia, fibroblast growth factor 23 and third-generation intravenous iron compounds: a narrative review. Drugs in Context, 2021, 10, 1-29.	2.2	19
56	Exercise programme to improve quality of life for patients with end-stage kidney disease receiving haemodialysis: the PEDAL RCT. Health Technology Assessment, 2021, 25, 1-52.	2.8	19
57	The Effects of Angiotensin Converting Enzyme Inhibitors on Potassium Homeostasis in Dialysis Patients With and Without Residual Renal Function. Artificial Organs, 2009, 33, 641-647.	1.9	18
58	A hospital-based cost minimization study of the potential financial impact on the UK health care system of introduction of iron isomaltoside 1000. Therapeutics and Clinical Risk Management, 2011, 7, 103.	2.0	18
59	Analysis of factors predicting mortality of new patients commencing renal replacement therapy 10 years of follow-up. BMC Nephrology, 2014, 15, 20.	1.8	18
60	Impact of Intravenous Iron on Oxidative Stress and Mitochondrial Function in Experimental Chronic Kidney Disease. Antioxidants, 2019, 8, 498.	5.1	17
61	Insulin resistance and altered glucose transporter 4 expression in experimental uremia. Kidney International, 2009, 75, 711-718.	5.2	16
62	Barriers to patient participation in a self-management and education website Renal PatientView: A questionnaire-based study of inactive users. International Journal of Medical Informatics, 2016, 87, 10-14.	3.3	16
63	Safety of Intravenous Iron â€“ Cosmofer and Monofer Therapy in Peritoneal Dialysis and Non-Dialysis-Dependent Chronic Kidney Disease Patients. Peritoneal Dialysis International, 2019, 39, 192-195.	2.3	15
64	Improving the safety of intravenous iron treatments for patients with chronic kidney disease. Expert Opinion on Drug Safety, 2021, 20, 23-35.	2.4	15
65	A multicentre prospective double blinded randomised controlled trial of intravenous iron (ferric) Tj ETQq1 1 0.784314 rgBT /Overlock 1C functional status. BMC Nephrology, 2021, 22, 115.	1.8	15
66	Point-of-care testing technologies for the home in chronic kidney disease: a narrative review. CKJ: Clinical Kidney Journal, 2021, 14, 2316-2331.	2.9	15
67	Cellular basis of uraemic cardiomyopathy: a role for erythropoietin?. European Journal of Heart Failure, 2009, 11, 732-738.	7.1	14
68	Finite element modeling of 3D-printed part with cellular internal structure using homogenized properties. Progress in Additive Manufacturing, 2019, 4, 143-154.	4.8	14
69	The role of patient portals in enhancing self-care in patients with renal conditions. CKJ: Clinical Kidney Journal, 2020, 13, 1-7.	2.9	14
70	Anemia in Peritoneal Dialysis Patients; Iron Repletion, Current and Future Therapies. Peritoneal Dialysis International, 2017, 37, 6-13.	2.3	13
71	Discrete-Event Simulation Thermal Model for Extrusion-Based Additive Manufacturing of PLA and ABS. Materials, 2020, 13, 4985.	2.9	13
72	Value of Carnitine Therapy in Kidney Dialysis Patients and Effects on Cardiac Function from Human and Animal Studies. Current Drug Targets, 2012, 13, 285-293.	2.1	12

#	Article	IF	Citations
73	Case Report: Crohn's-like Mycophenolate-Induced Colitis, a Fallout in Steroid-Free Regimens. Transplantation Proceedings, 2013, 45, 842-844.	0.6	12
74	Elasto-Plastic Finite Element Modeling of Short Carbon Fiber Reinforced 3D Printed Acrylonitrile Butadiene Styrene Composites. Jom, 2020, 72, 475-484.	1.9	12
75	Clarithromycin-induced granulomatous tubulointerstitial nephritis. Nephrology Dialysis Transplantation, 2006, 21, 2654-2655.	0.7	11
76	Can incremental haemodialysis reduce early mortality rates in patients starting maintenance haemodialysis?. Current Opinion in Nephrology and Hypertension, 2019, 28, 641-647.	2.0	11
77	Safety of ferric derisomaltose and iron sucrose in patients with iron deficiency anemia: The <scp>FERWONâ€IDA</scp>/<scp>NEPHRO</scp> trials. American Journal of Hematology, 2021, 96, E11-E15.	4.1	11
78	The comparative effects of intravenous iron on oxidative stress and inflammation in patients with chronic kidney disease and iron deficiency: a randomized controlled pilot study. Kidney Research and Clinical Practice, 2021, 40, 89-98.	2.2	11
79	Safety and Efficacy of Intravenous Ferric Derisomaltose Compared to Iron Sucrose for Iron Deficiency Anemia in Patients with Chronic Kidney Disease With and Without Heart Failure. American Journal of Cardiology, 2021, 152, 138-145.	1.6	11
80	Safety of Outpatient Kidney Biopsy: One Center'S Experience With 178 Native Kidney Biopsies. American Journal of Kidney Diseases, 2008, 52, 631-632.	1.9	10
81	Correlation of Iron Overload and Glomerular Filtration Rate Estimated by Cystatin C in Patients with Î²-Thalassemia Major. Hemoglobin, 2014, 38, 365-368.	0.8	10
82	NIMO-CKD-UK: a real-world, observational study of iron isomaltoside in patients with iron deficiency anaemia and chronic kidney disease. BMC Nephrology, 2020, 21, 539.	1.8	10
83	The PrEscription of intraDialytic exercise to improve quAlity of Life in patients with chronic kidney disease trial: study design and baseline data for a multicentre randomized controlled trial. CKJ: Clinical Kidney Journal, 2021, 14, 1345-1355.	2.9	10
84	Acute interstitial nephritis after COVID-19 vaccination. BMJ Case Reports, 2022, 15, e246841.	0.5	10
85	Functional and metabolic adaptation in uraemic cardiomyopathy. Frontiers in Bioscience - Elite, 2010, E2, 1492-1501.	1.8	9
86	Iron (III) isomaltoside 1000. Expert Review of Hematology, 2013, 6, 239-246.	2.2	9
87	SP321SAFETY OF IV IRON THERAPY IN CHRONIC KIDNEY DISEASE PATIENTS. Nephrology Dialysis Transplantation, 2016, 31, i197-i197.	0.7	9
88	Recent advances in drug discovery for diabetic kidney disease. Expert Opinion on Drug Discovery, 2021, 16, 447-461.	5.0	9
89	Heart Failure Hospitalization in Adults Receiving Hemodialysis and the Effect of Intravenous Iron Therapy. JACC: Heart Failure, 2021, 9, 518-527.	4.1	9
90	Acute interstitial nephritis induced by glucosamine. Nephrology Dialysis Transplantation, 2006, 21, 2031-2031.	0.7	8

#	Article	IF	Citations
91	Uremic cardiomyopathy is characterized by loss of the cardioprotective effects of insulin. American Journal of Physiology - Renal Physiology, 2012, 303, F1275-F1286.	2.7	8
92	Case Report: Guillain-Barrel•Syndrome following Renal Transplantation - A Diagnostic Dilemma. Nephron Clinical Practice, 2014, 124, 239-242.	2.3	8
93	Renal Squamous Cell Carcinoma of a Native Kidney After Renal Transplant: A Case Report. Transplantation Proceedings, 2016, 48, 259-261.	0.6	8
94	How Do We Navigate the Complexities Surrounding the Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Chronic Kidney Disease?. Mayo Clinic Proceedings, 2019, 94, 2166-2169.	3.0	8
95	Protocol and Baseline Data of a Multicentre Prospective Double-Blinded Randomized Study of Intravenous Iron on Functional Status in Patients with Chronic Kidney Disease. American Journal of Nephrology, 2020, 51, 493-500.	3.1	8
96	A single-centre audit of junior doctorsâ€™ diagnostic activity in medical admissions. Journal of the Royal College of Physicians of Edinburgh, The, 2009, 39, 307-312.	0.6	8
97	Surgical Correction of Nephrotic Syndrome. Nephron, 2001, 87, 291-292.	1.8	7
98	Early Mortality Rates After Commencement of Maintenance Hemodialysis: A Systematic Review and Metaâ€Analysis. Therapeutic Apheresis and Dialysis, 2020, 24, 275-284.	0.9	7
99	Stroke in hemodialysis patients randomized to different intravenous iron strategies: a prespecified analysis from the PIVOTAL trial. Kidney360, 2021, 2, 10.34067/KID.0004272021.	2.1	7
100	Analysis of oxidative stress, inflammation and endothelial function following intravenous iron in chronic kidney disease in the Iron and Heart Trial. Scientific Reports, 2022, 12, 6853.	3.3	7
101	The man who gained a stone. Nephrology Dialysis Transplantation, 2003, 18, 434-435.	0.7	6
102	Carcinoma of the bronchus presenting as renal failure secondary to amyloidosis. Nephrology Dialysis Transplantation, 2003, 18, 1031-1031.	0.7	6
103	Perspectives on eGFR reporting from the Interface between Primary and Secondary Care. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 258-260.	4.5	6
104	Beyond efficacy and safety--the need for convenient and cost-effective iron therapy in health care. CKJ: Clinical Kidney Journal, 2011, 4, i14-i19.	2.9	6
105	Data confusion. Kidney International, 2015, 88, 1445.	5.2	6
106	The Use of Automated Electronic Alerts in Studying Short-Term Outcomes Associated with Community-Acquired Acute Kidney Injury. Nephron, 2017, 135, 181-188.	1.8	6
107	A 6 month extension trial evaluating safety and efficacy of ferric derisomaltose in patients with iron deficiency anemia: The <scp>FERWONâ€EXT</scp> trial. American Journal of Hematology, 2020, 95, E276.	4.1	6
108	Arterio-Venous Fistula: Is it Critical for Prolonged Survival in the over 80's Starting Haemodialysis?. PLoS ONE, 2016, 11, e0163487.	2.5	6

#	Article	IF	Citations
109	Influence of Intravenous Iron Therapy on Novel Markers of Iron Deficiency. International Journal of Artificial Organs, 2010, 33, 297-301.	1.4	5
110	An evaluation of ferric derisomaltose as a treatment for anemia. Expert Review of Hematology, 2021, 14, 7-29.	2.2	5
111	Potassium responses to sodium zirconium cyclosilicate in hyperkalemic hemodialysis patients: post-hoc analysis of DIALIZE. BMC Nephrology, 2022, 23, 59.	1.8	5
112	Atherosclerotic renovascular disease in the elderly: angioplasty with stenting versus reconstructive surgery. Geriatric Nephrology and Urology, 1997, 7, 87-94.	0.3	4
113	Interpreting and investigating proteinuria. BMJ, The, 2012, 344, e2339-e2339.	6.0	4
114	Deferasirox and renal dysfunction in children. Pediatric Nephrology, 2012, 27, 2159-2159.	1.7	4
115	Iron therapy in patients with chronic kidney disease. Transfusion Alternatives in Transfusion Medicine, 2012, 12, 115-121.	0.2	4
116	Deferiprone, iron overload in a renal transplant patient. QJM - Monthly Journal of the Association of Physicians, 2014, 107, 465-466.	0.5	4
117	The Impact of Lowering Haemoglobin Targets on Patterns of Erythropoiesis-Stimulating Agent Use in Patients on Haemodialysis. Blood Purification, 2016, 41, 287-292.	1.8	4
118	Protocol and baseline data for a prospective open-label explorative randomized single-center comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (IRON-CKD). Trials, 2019, 20, 194.	1.6	4
119	Reasons for COVID-19 vaccination hesitancy in hemodialysis patients. Kidney International, 2021, 100, 702.	5.2	4
120	Influences of the N- and C-Termini of the Distal Nephron Inward Rectifier, ROMK. Kidney and Blood Pressure Research, 2001, 24, 142-148.	2.0	3
121	Bolus intraperitoneal iron versus intravenous iron in peritoneal dialysis patients: a prospective study. Transfusion Alternatives in Transfusion Medicine, 2007, 9, 101-107.	0.2	3
122	THE USE OF PHARMACEUTICALS FOR DIALYSIS PATIENTS. HOW WELL DO WE KNOW OUR PATIENTS' ALLERGIES?. Journal of Renal Care, 2008, 34, 213-217.	1.2	3
123	Prevalence of modifiable cardiovascular risk factors in long-term renal transplant patients. International Journal of Nephrology and Renovascular Disease, 2010, 3, 175.	1.8	3
124	The effect of spontaneous twin pregnancy on renal transplant function and haemodynamics. CKJ: Clinical Kidney Journal, 2010, 3, 48-50.	2.9	3
125	Renal function after new treatment with renin-angiotensin system blockers. BMJ: British Medical Journal, 2017, 356, j1122.	2.3	3
126	Conversion of haemodialysis patients from iron sucrose to iron isomaltoside: a real-world experience. BMC Nephrology, 2020, 21, 212.	1.8	3

#	Article	IF	Citations
127	A mixed-method feasibility study of a novel transitional regime of incremental haemodialysis: study design and protocol. Clinical and Experimental Nephrology, 2021, 25, 1131-1141.	1.6	3
128	Falling Usage of Hospital-Based Emergency Care during the Covid-19 Pandemic in the Uk. Journal of the Royal College of Physicians of Edinburgh, The, 2020, 50, 210-212.	0.6	3
129	The effect of digoxin on renal function in patients with heart failure. BMC Nephrology, 2021, 22, 349.	1.8	3
130	Counselling Prior to Blood-Borne Virus Screening in Haemodialysis Patients: A Survey of Patient Experience and Opinion. Nephron Clinical Practice, 2009, 112, c94-c97.	2.3	2
131	Investigating polyuria. BMJ, The, 2013, 347, f6772-f6772.	6.0	2
132	Examining Determinants of Patient Outcome in a Low Clearance Clinic. Nephron, 2015, 129, 263-268.	1.8	2
133	Correction of iron deficiency anaemia using IV CosmoFer in CKD patients with asthma: a prospective study. QJM - Monthly Journal of the Association of Physicians, 2016, 109, 187-190.	0.5	2
134	Getting the basics right: the monitoring of arteriovenous fistulae, a review of the evidence. Current Opinion in Nephrology and Hypertension, 2020, 29, 564-571.	2.0	2
135	Age, Gender and Diabetes as Risk Factors for Early Mortality in Dialysis Patients: A Systematic Review. Clinical Medicine and Research, 2021, 19, 54-63.	0.8	2
136	The Impact of Intravenous Iron on Renal Injury and Function Markers in Patients With Chronic Kidney Disease and Iron Deficiency Without Anemia. Kidney International Reports, 2022, 7, 322-326.	0.8	2
137	Biophysical effects of pore mutations of ROMK1. Clinical Science, 2001, 101, 121.	4.3	1
138	U-shaped effect of eGFR and mortality. Kidney International, 2012, 81, 1152.	5.2	1
139	South Asian hospitals that lack DNAR orders deny patients holistic care. BMJ, The, 2013, 347, f6300-f6300.	6.0	1
140	Happy, â€˜healthyâ€™ and enjoying life on dialysis: an elderly perspective. International Urology and Nephrology, 2014, 46, 1035-1036.	1.4	1
141	P0858A MULTICENTRE PROSPECTIVE DOUBLE BLIND RANDOMISED CONTROLLED TRIAL OF INTRAVENOUS IRON IN IRON DEFICIENT BUT NOT ANAEMIC PATIENTS WITH CHRONIC KIDNEY DISEASE ON FUNCTIONAL STATUS. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	1
142	P0331ASSESSMENT OF DELIVERY OF NICE APPROVED USE OF TOLVAPTAN (JINARC) IN ADULTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE IN A UK RENAL CENTRE. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	1
143	The impact of e-alerts on inpatient diagnosis and management of acute kidney injury. British Journal of Hospital Medicine (London, England: 2005), 2021, 82, 1-11.	0.5	1
144	Dose effect analysis of sodium zirconium cyclosilicate in hemodialysis patients. Hemodialysis International, 2022, 26, 274-277.	0.9	1

#	Article	IF	Citations
145	RACTK1: a putative inward rectifier potassium channel of the distal nephron. Investigation in Xenopus laevis oocytes. Nephrology, 2001, 6, 285-289.	1.6	0
146	Aldosterone blockade: the heart versus the kidney. Kidney International, 2012, 82, 1136.	5.2	0
147	SP537EVALUATION OF THE TRAINING RECEIVED BY RENAL TRAINEES IN DIALYSIS LINE INSERTION. Nephrology Dialysis Transplantation, 2016, 31, i271-i272.	0.7	0
148	P0851THE DIFFERENTIAL IMPACT OF INTRAVENOUS IRON IN A MODEL OF EXPERIMENTAL URAEMIA ON TISSUE MARKERS OF OXIDATIVE STRESS. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
149	SO051PROSPECTIVE OPEN-LABEL EXPLORATIVE RANDOMISED SINGLE CENTRE COMPARATIVE STUDY TO DETERMINE THE EFFECTS OF VARIOUS INTRAVENOUS IRON PREPARATIONS ON HAEMOGLOBIN, HAEMETENICS, MARKERS OF KIDNEY FUNCTION, QUALITY OF LIFE AND SAFETY. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
150	MO016MYOCARDIAL INFARCTION IN THE PIVOTAL STUDY OF IV IRON IN HAEMODIALYSIS: A PRE-SPECIFIED SECONDARY ANALYSIS. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
151	P0848PROSPECTIVE OPEN-LABEL EXPLORATIVE RANDOMISED SINGLE-CENTRE COMPARATIVE STUDY TO DETERMINE THE EFFECTS OF VARIOUS INTRAVENOUS IRON PREPARATIONS ON MARKERS OF OXIDATIVE STRESS AND KIDNEY INJURY IN CHRONIC KIDNEY DISEASE (IRON-CKD). Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
152	MO015HAEMODIALYSIS VASCULAR ACCESS THROMBOSIS: AN ANALYSIS OF EVENTS FROM THE PROACTIVE IV IRON THERAPY IN HAEMODIALYSIS PATIENTS (PIVOTAL) TRIAL. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
153	MO201ANALYSIS OF USAGE OF SODIUM ZIRCONIUM CYCLOSILICATE (SZC) AT HULL UNIVERSITY TEACHING HOSPITALS. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
154	FC 096THE EFFECT OF INCREMENTAL START OF HAEMODIALYSIS ON BLOOD PRESSURE AND INTERDIALYTIC WEIGHT GAIN: PRELIMINARY FINDINGS FROM THE ENDURE STUDY. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
155	INCREASED CAESIUM SENSITIVITY OF ROMK1 BY MUTATIONS OF THE PORE RESIDUE GLYCINE 143 (G143). Nephrology, 2000, 5, A110-A110.	1.6	0
156	KARYOMEGALIC NEPHROPATHY A RARE CAUSE OF RENAL FAILURE â€•HLA AND PLOIDY ANALYSIS. Nephrology, 2000, 5, A109-A109.	1.6	0
157	INCREASED BARIUM SENSITIVITY OF ROMK1 BY POINT MUTATIONS OF GLYCINE 143. Nephrology, 2000, 5, A100-A100.	1.6	0
158	Hypokalemia Events With Sodium Zirconium Cyclosilicate and Placebo in Hemodialysis Patients. Kidney International Reports, 2022, 7, 908-912.	0.8	0
159	The prevalence and potential aetiological factors associated with restless legs syndrome in patients with chronic kidney disease: a cross-sectional study. International Urology and Nephrology, 2022, , 1.	1.4	0
160	Managing persistent hyperkalaemia with next-generation potassium binders. Journal of Kidney Care, 2022, 7, S1-S18.	0.1	0